NeuroBo Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2014-01-01
- Employees
- 8
- Market Cap
- -
- Website
- http://www.neurobopharma.com
- Introduction
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers
- Conditions
- Hypercholesteremia
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02587416
The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects
- First Posted Date
- 2015-10-26
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT02586168
Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides
- Conditions
- HypercholesterolemiaHypertriglyceridemia
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 161
- Registration Number
- NCT02585869
Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients on Stable Statin Therapy
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2020-04-09
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 66
- Registration Number
- NCT02571257
Study of DA-9801 to Treat Diabetic Neuropathy
- Conditions
- Diabetic Neuropathy
- Interventions
- Drug: DA-9801 600mgDrug: PlaceboDrug: DA-9801 900mgDrug: DA-9801 300mg
- First Posted Date
- 2013-04-04
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- NeuroBo Pharmaceuticals Inc.
- Target Recruit Count
- 128
- Registration Number
- NCT01822925
- Locations
- 🇺🇸
Diablo Clinical Research, Walnut Creek, California, United States
🇺🇸Center for United Research, Inc., Lakewood, California, United States
🇺🇸Clinical Research Consulting, LLC, Milford, Connecticut, United States